会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • TOXOPLASMA GONDII GLYCOCONJUGATES
    • 豆科植物GONDII GLYCOCONJUGATES
    • WO1997010249A1
    • 1997-03-20
    • PCT/EP1996004034
    • 1996-09-12
    • AKZO NOBEL N.V.KOOLEN, Marcus, Josephus, MarieDAMM, Jan, Bas, LouisSTRIEPEN, BorisSCHWARZ, Ralph, T.
    • AKZO NOBEL N.V.
    • C07H03/06
    • A61K39/002C07H3/06C07K16/20
    • The present invention relates to a glycoconjugate immunoreactive with Toxoplasma gondii antibodies, (monoclonal) antibodies against these glycoconjugates, and cell lines capable of producing monoclonal antibodies. The invention is further concerned with immunochemical reagents and methods for the detection of T. gondii or antibodies directed agains T. gondii. Furthermore the invention relates to a therapeutic reagent for the inhibition of replication of T. gondii parasites and a method for the production of a live attenuated T. gondii vaccine. It has now been found, and in contrast with earlier publications in this art, that several glycoconjugates are immunoreactive with Toxoplasma gondii specific antibodies comprising a glycan core structure having general formula (I) wherein R1 = Hydrogen, -PO3-CH2-CH2-NH2 (ethanolamine-phosphate), or -PO3-CH2-CH2-NH-X, wherein X = a T. gondii specific antigen; wherein R2 = alpha -O-R4, alpha (1-4)-O-anhydromannitol or alpha (1-4)-O-glucoseamine optionally alpha (1-6)-linked to the inositol moiety of a phosphatidylinositol membrane anchor; wherein R3 = a monosaccharide moiety, wherein R4 = Hydrogen or -L-R5, wherein L = a bivalent organic radical and R5 = a functional group that allows coupling to a carrier. A preferred embodiment of the monosaccharide moiety is a hexose moiety, more preferred is a glucose moiety, and most preferred is a glucose moiety which is bonded to the GalNAc-moiety by an alpha -1,4 glycosidic bond. It has been found that the glycoconjugates according to the present invention are particularly suitable for diagnosing T. gondii infected humans.
    • 本发明涉及与弓形体弓形体抗体免疫反应的糖缀合物,针对这些糖缀合物的(单克隆)抗体,以及能够产生单克隆抗体的细胞系。 本发明进一步涉及免疫化学试剂和用于检测弓形虫或再次引导弓形虫的抗体的方法。 此外,本发明涉及用于抑制弓形虫寄生虫复制的治疗试剂和一种减毒活的弓形虫疫苗的生产方法。 现在已经发现,与本领域的早期出版物相反,几种糖缀合物与弓形体特异性抗体是免疫反应的,其包含通式(I)的聚糖核心结构,其中R1 =氢,-PO3-CH2-CH2-NH2 (乙醇胺 - 磷酸盐)或-PO 3 -CH 2 -CH 2 -NH-X,其中X =弓形虫特异性抗原; 其中R2 =α-O-R4,α(1-4)-O-脱水脱水葡萄糖醇或任选α(1-6)连接至磷脂酰肌醇膜锚的肌醇部分的α(1-4)-O-葡萄糖胺; 其中R3 =单糖部分,其中R4 =氢或-L-R5,其中L =二价有机基团,R5 =允许与载体结合的官能团。 单糖部分的优选实施方案是己糖部分,更优选葡萄糖部分,最优选的是通过α-1,4糖苷键与GalNAc部分结合的葡萄糖部分。 已经发现根据本发明的糖缀合物特别适用于诊断弓形虫感染的人。